NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on innovative cancer therapies, announced the granting of inducement awards for new employees as part of its 2023 Inducement Plan. On May 1, 2025, the company granted options to purchase up to 188,100 shares of common stock to seven new employees. These stock options will vest over a four-year period, with 25% of the shares vesting after one year and the remainder vesting monthly over the following 36 months, contingent upon the employees' ongoing service with Syndax.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442293-en) on May 02, 2025, and is solely responsible for the information contained therein.